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ABSTRACT
Clinical management of skin-containing vascularized composite allografts (VCA) requires
accurate assessment of the graft status, typically based on skin biopsies. The Banff 2007
Working Classification proposed 4 grades of acute rejection, but did not score individual
features or include vascular rejection. Here we report a systematic scoring system developed
from MHC-mismatched porcine skin-containing VCA. Biopsies from 20 VCA, 9 autologous skin
flaps and 9 normal skin were analyzed to optimize the methodology and set thresholds. The
components quantified were: perivascular cells/dermal vessel (pc), perivascular dermal infiltrate
area (pa), luminal leukocytes/capillary or venule (c), epidermal infiltrate (ei), epidermal apoptosis
or necrosis (e), endarteritis (v), and chronic allograft vasculopathy (cav). To evaluate prognostic
value, we scored a separate group of 28 serial biopsies from 8 recipients (4 that were ultimately
accepted and 4 that rejected. Parameters on the initial biopsies predicting later graft rejection
included pc (p < 0.02), pa (p < 0.03), ei (p < 0.0005), e (p < 0.003) and c (p < 0.005).
Reproducibility between 2 pathologists blinded to clinical data was acceptable, with weighted
kappa scores for pc (0.673), pa (0.399), ei (0.464), e (0.663), v (0.766), and c (0.642). This
component scoring system can be adapted clinically, since human and porcine skin are highly
similar. Vascular lesions in VCA are also highlighted in this system and could impact graft
outcome. The component score approach complements Banff 2007 grades and will enable the
establishment of clinically significant thresholds.
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Introduction
Assessment of skin-containing VCA status is currently
performed by visual inspection and skin biopsies.
Clinical and pathologic features have been described
in both human and experimental settings1-3 and these
features were integral to the formulation of the Banff
2007 Working Classification for composite tissue
allografts.4,5 Banff 2007 grades are based on combina-
tions of epidermal infiltrates, epidermal apoptosis and
dermal/perivascular infiltrates. These are not scored
separately and do not include vascular inflammation,
nor have been formally tested for reproducibility or
clinical significance.
Evaluation of individual pathologic components
through systematic semi-quantitative scores offers
the opportunity to define grades of the separate
pathologic lesions (rather than mild moderate
severe), refine criteria of rejection, identify distinc-
tive patterns of rejection, increase reproducibility
between centers, and provide a detailed data struc-
ture for reporting clinical and experimental
research. We have developed a pathologic compo-
nent scoring system based on experimental studies
in porcine skin-containing VCA that is reproducible
and predictive of graft loss. It includes the features
considered in the Banff 2007 Working Classification
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(plus vascular lesions) and is potentially suitable for
assessing human skin-containing VCA.
Materials and methods
Animals
MGH miniature swine were bred in a specific patho-
gen-free facility with defined MHC while maintaining
minor antigen variation.6 Animals were housed at the
Transplantation Biology Research Center in accor-
dance with the Guide for the Care and Use of Labora-
tory Animals. All experiments were conducted with
the approval of the Institutional Animal Care and Use
Committee of the MGH.
VCA transplantation
A fasciocutaneous vascularized composite allotrans-
plant model was used. Donor animals were placed
under general anesthesia, positioned supine with the
hind limbs extended and prepared for surgery. A skin
island of approximately 12 £ 8 cm was elevated, with
the underlying subcutaneous tissue and fascia, on a vas-
cular pedicle comprising the medial saphenous artery
and veins to their junctions with the superficial femoral
vessels, which were recovered to a length of 2 cm to
facilitate anastomosis. Flaps were recovered and flushed
with 100 U/mL heparin sulfate in 0.9% normal saline.
Defects were prepared in the recipients and donor ves-
sels anastomosed to the carotid artery/internal jugular
vein using standard microsurgical techniques. VCA
outcome was followed by clinical appearance, protocol
biopsy, with additional biopsies at times of clinically
suspected acute rejection. The autologous skin flaps
were raised from the groin and are perforator flaps
based on the medial saphenous artery and vein. Native
skin biopsies were also taken from the groin.
Treatment protocols
Group A included 4 animals (20680, 20681, 21556 and
21557; A1–4, respectively) that were haploidentical
donor/recipient combinations selected from the MGH
inbred miniature swine herd, treated on a mixed-
chimerism protocol to induce transplant tolerance.6
The treatment protocol for Group A animals included
CD3-Immunotoxin 50ug/kg twice daily day -4 to -1,
100cGy TBI day -2, haematopoietic cell transplant
(HCT) day 0–2 at 15 £ 109 cells/kg, followed by VCA
on day 3. HCT was with cytokine mobilized pBMC
collected from donors by leukapheresis after mobiliza-
tion with pIL3 and pSCF injected IM at dose of 100ug/
kg to 30kg body weight, then 50ug/kg for each addi-
tional kg. Group B included 3 animals on related treat-
ment protocols: Animal B1 (22667) was on the same
conditioning protocol as Group A, but received a class
I MHC mismatched transplant. Animal B2 (22419)
received the same conditioning as Group A and
received a haploidentical, unmobilized haematopoietic
cell transplant (HCT). Animal B3 (21656) also received
the same conditioning as Group A and received a hap-
loidentical, bone marrow transplant (BMT). The fourth
animal, B4 (22183), was a control animal that received
a haploidentical VCA and no treatment.
The VCA of animals from Group A were accepted
without clinical evidence of rejection throughout fol-
low up (mean 293 days, range 139–486). The VCA of
animals from Group B were ultimately rejected, fol-
lowing modest prolongation of survival by the treat-
ment protocols (mean survival 40 days, range 8–63).
Pathologic evaluation
A total of 66 biopsy samples were analyzed (Fig. 1).
Nine autologous skin flaps and 9 native skin biopsies
Figure 1. Development of the pathologic component scoring system and evaluation for prognostic value and reproducibility.
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were used to develop minimum thresholds and 20
VCA biopsies with known rejection were used to
further establish other pathologic components and
corresponding ranges and scores. To evaluate for
prognosis and reproducibility, 28 serial VCA biopsies
from 8 animals were reviewed and scored. Six mm
punch biopsies were placed in formalin and proc-
essed by routine histologic methods, followed by
hematoxylin and eosin staining. Quantification of
cells was done at 20x and 40x magnification using
a BX53 microscope (Olympus, Center Valley, PA).
The field diameter of the 20x field was 1.325 mm
and the 40x was 0.6625 mm. C4d staining was not
done due to lack of a suitable antibody for porcine
C4d.
Development of the scoring system
Threshold values and pathologic patterns of cell
infiltration (Table 1)
To establish threshold values for normal skin and
nonimmunologic graft inflammation for each of the
pathologic components, skin punch biopsies from 9
porcine autologous skin flaps and 9 porcine native
skin were reviewed and assessed for amount of mono-
nuclear cells and patterns of cell infiltration.
The perivascular infiltrate was assessed in 2 different
ways. First, the mononuclear cells surrounding dermal
vessels (arterioles, venules and capillaries) were
counted at 40x magnification in at least 4 random areas
(pc). The mean number of perivascular mononuclear
cells was calculated as (n1C n2C n3C n4)/4, where n
represents total number of perivascular mononuclear
cells per vessel in a 40x field. In the second method, the
perivascular infiltrate area (pa) was expressed as the
percentage occupied by the perivascular infiltrate at
40x magnification in a given discrete collection of der-
mal vessels and was scored in the most involved area.
The score for ei was determined by counting the
number of mononuclear cells within the full length of
the epidermis at 20x magnification. The number of
mononuclear cells in the epidermis was calculated
as N D n1 C n2 C n3 C n4…, where n represents
number of mononuclear cells per 20x field and N is
the total number of cells in all fields spanning the
epidermis, expressed as the number of cells per 4 20x
fields (typical of a 6 mm punch biopsy).
The number of leukocytes inside capillary lumina
or venules (c) was counted in at least 4 fields at 40x
magnification and the mean numbers calculated. This
is similar to the capillaritis (ptc or microvascular
inflammation) score in the Banff kidney classification.
This is not the same as the “capillaritis” used by der-
matopathologists that requires changes in the capillary
wall. The c score was evaluated by assessing all
capillaries in the sample and taking the value of the
most involved capillary.
Evaluation for any epidermal injury (e), endothelia-
litis (v) and chronic allograft vasculopathy (cav) was
also done. The scores for epidermal injury (e) were
determined by the presence of single keratinocyte
Table 1. Definitions of pathological components and scores.
Component Definition and Scoring
pc perivascular cells – number of cells surrounding dermal
vessels (capillaries, venules and arterioles) in the
superficial and deep dermis; scored on the most involved
vessels
pc0 <10 cells/vessel
pc1 10–25 cells/vessel
pc2 26–50 cells/vessel
pc3 >50 cells/vessel
pa perivascular dermal infiltrate area – expressed as percent
area occupied by the most involved dermal vessels at 40x
magnification (example on Fig. 4D)
pa0 <25%
pa1 25–50%
pa2 50–75%
pa3 >75%
ei epidermal infiltrate – total number of mononuclear cells per
4 20x fields
ei0 <10 cells
ei1 10–20 cells
ei2 >20 cells
ei3 transepidermal infiltrate
eix no epidermis
v endarteritis – mononuclear cells underneath arterial
endothelium; scored on the most involved artery,
arterioles not scored
v0 none
v1 <25% of lumen/vessel
v2 >25% of lumen/vessel
v3 fibrinoid necrosis/transmural involvement
vx no arteries
e epidermal injury and necrosis – presence of keratinocyte
apoptosis and necrosis
e0 none
e1 apoptosis
e2 focal necrosis
e3 sloughed
cav chronic allograft vasculopathy – intimal thickening with
luminal reduction; scored as percent
luminal reduction
cav0 none
cav1 <25% luminal reduction
cav2 25–50% luminal reduction
cav3 >50% luminal reduction
cavx no arteries
c capillaritis – maximum number of cells per capillary cross
section; scored on most involved capillaries
c0 0–1/capillary
c1 2–4/capillary
c2 5–10/capillary
c3 >10/capillary
ct thrombi
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apoptosis or extent of necrosis. Endarteritis (v) and
chronic allograft vasculopathy (cav) scores were
adapted from the v and cav scores of the Banff 2013
Classification for kidney allografts.7
Optimization of the scoring system
To optimize the schema and to establish ranges for the
component scores, similar methods were used to eval-
uate for pc, pa, ei, e, v and cav on 20 porcine skin-
containing VCA indication punch biopsies with a
spectrum of grades of rejection by Banff 2007 Work-
ing Classification. The 20 VCA samples included 16
with Grade I - IV rejection and 4 with Grade 0 rejec-
tion. Pathologic patterns and other features were also
noted. Five of the 16 biopsies had Grade I rejection, 7
with Grade II rejection, 3 with Grade III rejection and
1 with Grade IV rejection.
The mean values obtained from the native skin
biopsies, autologous skin flap biopsies and VCA biop-
sies with known Banff Grade 0 - IV rejection were
used to establish the pathologic components and to
assign cutoff values and ranges for the scores.
Reproducibility
To test for reproducibility, 28 serial biopsies from 8
animals (Group A and Group B) were coded and
scored by 2 pathologists blinded to the various treat-
ment protocols, gross features and outcome.
Evaluating for prognostic value of pathologic
components
To evaluate the prognostic value of this schema, we
compared the scores of the first biopsies of 4 allografts
from Group A that were subsequently accepted (mean
follow-up of 293 days) and 4 allografts from Group B
that rejected (mean graft survival of 40 days)
(Table 2).
Statistical analysis was performed using GraphPad
Prism 7 software (Graphpad Software Inc., La Jolla,
CA). Mann-Whitney U test was used for comparisons.
A p value of less than 0.05 was considered statistically
significant.
Results
The pathological component scoring system
Thresholds and pathologic patterns of cell infiltration
Native skin biopsies typically showed epidermal
mononuclear infiltrates ranging from 1 - 9 cells
counted at 20x magnification over the full length of
the epidermis or an average of 4 cells per 4 20x fields.
Seven autologous skin flap biopsies taken at >15 d
post-transplant showed a higher range of 5 – 15 cells
over the full length of the epidermis or an average of
10 cells per four 20x fields, while 2 other autologous
skin flap biopsies taken at earlier time points showed
an average of 22 cells per four 20x fields (Fig. 2). In
autologous skin flap biopsies, epidermal inflammatory
cells are seen in greater numbers in focal distribution
in comparison to native skin where they are usually
more uniform along the length of the epidermis. Tak-
ing the means of the total number of epidermal mono-
nuclear cells in both native skin and autologous skin
flaps, the number of epidermal mononuclear cells for
a score of ei0 was established at <10 cells over the full
length of the epidermis or per 4 medium power (20x)
fields. Capillaries showed a mean of 1 intracapillary
cell in both native and autologous skin flap biopsies.
None of the native skin or autologous skin flap biop-
sies showed endothelialitis. None had apoptotic cells.
Table 2. Pathologic component scores of first biopsies between 2 groups.
Pathologic Component Scores
Animal number Gross Appearance
Days
post-transplant pc pa ei e v c cav
Graft survival
(number of days)
Group A
A1 Indistinguishable from surrounding skin POD 56 0 0 0 0 0 0 0 486 days
A2 Indistinguishable from surrounding skin POD 58 0 0 0 0 0 0 0 139 days
A3 Mild edema POD 13 0 1 0 0 0 0 0 275 days
A4 Mild edema POD 13 1 1 0 0 0 0 0 275 days
Group B
B1 Edema POD 14 1 1 1 2 0 2 0 40 days
B2 Edema POD 15 2 3 2 1 0 2 0 50 days
B3 Erythema, induration POD 42 3 3 2 1 0 2 0 63 days
B4 Erythema POD 2 2 2 2 1 2 2 0 8 days
No evidence of rejection at end of experimental follow up
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In the 20 VCA indication biopsies, 4 did not show
evidence of rejection and were classified as Banff
Grade 0. The perivascular infiltrate (pc) had a mean of
2 cells/vessel and the biopsies did not show edema.
The epidermal infiltrate (ei) was an average of 3 cells
per four 20x fields. Capillaries had 0 - 1 intraluminal
cells.
Five of the 20 VCA indication biopsies had Banff
2007 Grade I rejection, all of which showing superfi-
cial dermal edema. The amount of perivascular infil-
trate ranged from 8–15 cells/vessel with a mean of 10
cells/vessel. The perivascular dermal infiltrate area
(pa) in the most involved vessels showed a range of
20–70% of a 40x field with a mean of 46%. The epider-
mal infiltrate had an average of 11 cells per four 20x
fields. One biopsy had 25 cells in the epidermis but
showed only a mild perivascular infiltrate and there-
fore did not meet criteria for Banff Grade 2 rejection.
Eosinophils were occasionally seen in the perivascular
infiltrate. None of the biopsies had endothelialitis.
Capillaries showed a mean of 4 intracapillary cells in
the most involved capillary. Two biopsies showed neu-
trophils in capillaries.
Seven of the 20 VCA indication biopsies had Grade
II rejection and showed different patterns. All the
biopsies showed edema, which was prominent in the
superficial dermis in 5 biopsies and was localized to
the subcutaneous region in 2 biopsies. All showed
increased mononuclear infiltrates around the dermal
vessels, the most involved regions showing a range of
20–80% of a 40x field with a mean of 52%. Mast cells
and occasional eosinophils were also present in the
perivascular infiltrate. Four showed discrete and mod-
erate epidermal inflammation, which were evident at
10x magnification. In these biopsies, the mean number
of cells in the epidermal infiltrate was 20 cells per 4
20x fields. In 2 biopsies, the infiltrate was focal but
transepidermal. Two biopsies which were diagnosed
as Banff 2007 Grade II or III rejection had a single
apoptotic keratinocyte. In general, these patterns dem-
onstrate that perivascular or epidermal inflammation
can be dominant with one being more pronounced
than the other. The global grades of rejection in the
Banff 2007 Working Classification required degrees of
perivascular inflammation to be present, with or with-
out epidermal inflammation, but these did not always
occur together. Five of the 7 biopsies had endarteritis,
one of which also showed early chronic allograft vas-
culopathy (cav). Intracapillary cell counts ranged from
4–6 cells in the most involved capillaries.
Three biopsies with Banff 2007 Grade III rejection
and one with Grade IV rejection were reviewed. All
showed severe and diffuse epidermal infiltration and
full thickness epidermal involvement. Two had multi-
ple foci of epidermal apoptosis. Perivascular inflam-
mation was also extensive and severe. The biopsy with
Grade IV rejection showed frank epidermal necrosis
and mononuclear cell infiltration of hair follicles and
adnexal glands. Transmural endarteritis was seen in 2
of the 3 biopsies with Grade III rejection and in the
biopsy that showed Grade IV rejection. Chronic allo-
graft vasculopathy was present in the biopsy with
Grade IV rejection. Capillaritis was diffuse in both
Grade III and IV rejection, with a maximum of 8 cells
in the most involved capillary. Capillary thrombosis
was present in the biopsy with Grade IV rejection.
Spongiosis was seen in some of the biopsies with
Grade II-IV rejection but not consistently throughout
the samples that showed rejection of the VCA. The
component scores for the biopsies with different
grades of rejection are summarized in Fig. 3.
Thus, consolidating the means and ranges obtained,
including pathologic patterns, the components for the
scoring system were established as follows: perivascu-
lar cells/dermal vessel (pc), perivascular dermal infil-
trate area (pa), luminal leukocytes/capillary or venule
(c), epidermal infiltrate (ei), epidermal apoptosis or
necrosis (e), endarteritis (v), and chronic allograft vas-
culopathy (cav). The definition of these components,
the scores and corresponding ranges are listed in
Table 1. Representative images pathologic compo-
nents and corresponding scores are in Figs. 4, 5 and 6.
Reproducibility and ease of use
The weighted kappa scores showed moderate to sub-
stantial agreement for pc (0.673), pa (0.399), ei
(0.464), e (0.663), v (0.766), and c (0.642). With
Figure 2. Number of epidermal mononuclear cells per 4 medium
power (20x) fields in native and autologous skin flaps
66 I. A. ROSALES ET AL.
experience, the scoring could be done easily and effi-
ciently, which for the study pathologists was less than
10 minutes.
Evolution of pathologic lesions
To follow the evolution of the pathological lesions,
serial biopsies were reviewed from grafts that rejected
or were accepted for >100 d. Protocol biopsies from
allografts from Group A that rejected in a mean of 40
d showed higher pathologic component scores than
allografts from Group B that were accepted and sur-
vived for more than 100 d. Perivascular inflammation
(pc, pa) and epidermal involvement (ei, e) scores
showed an increasing trend over time as the grafts
rejected. Vascular inflammation scores (c, v) also
showed the same pattern and appeared to show higher
scores even at early time points (Figs. 7 and 8). None
of the biopsies in this cohort showed chronic allograft
vasculopathy.
Evaluation for prognostic value of pathologic
components
Component scores of the initial protocol biopsies were
analyzed in relation to outcome in groups A and B
Figure 3. Pathologic component scores across 20 VCA biopsies with different Banff grades of rejection.
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Figure 4. Histologic features of porcine skin and skin-containing VCA and pathologic component scores. A) Normal pig skin, punch
biopsy. B) Minimal perivascular infiltrate (pc0) with capillaritis (c1) (arrows) in the superficial dermis. C) Moderately dense perivascular
inflammation (pc2) with more evident capillaritis (c2) (arrows) at 40x magnification. D) The perivascular infiltrate surrounds dilated
superficial dermal capillaries (pc1) occupying more than half of the field at 40x magnification (pa2) (outlined in blue). Dilated capillaries
show occasional intraluminal mononuclear cells (c1) (arrows).
Figure 5. Epidermal inflammation (ei) and injury (e) in skin-containing VCA. A) Epidermis at 40x magnification with no epidermal infil-
trate (ei0). Dilated superficial dermal capillaries with minimal perivascular inflammation are also present. B) One focus of prominent epi-
dermal involvement without apoptosis (ei3, e0). C and D) Focal keratinocyte apoptosis (e1) (arrows). E) Frank epidermal necrosis.
Moderate perivascular inflammation in the superficial dermis is also present.
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(clinical acceptance versus rejection). The following
parameters were identified as predictive of graft rejec-
tion: pc (p < 0.02), pa (p < 0.03), ei (p < 0.0005),
e (p < 0.003) and c (p < 0.005) in biopsies taken at a
mean of 18 d for rejected grafts and 35 d for accepted
grafts. Vascular v and cav lesions were not seen in any
of the serial biopsy samples. Similar trends, although
not statistically significant, were seen in the initial
biopsies taken at the same time (13–15 days).
Discussion
Experimental studies on skin have long used pig skin
because of its striking similarities to human skin. This
applies to its general structure, thickness, hair follicle
content, pigmentation, collagen and lipid composi-
tion.8 Porcine epidermal thickness, for example, has
been shown to approximate human epidermis, and
range from 30 to 140 mm, which is comparable to
human skin thickness of 50–120 mm.8 It is thus
optimal to use porcine skin-containing VCA as a
platform for establishing pathologic components for
scoring systems.
The Banff 2007 Working Classification for Vascu-
larized Composite Tissue Allografts was developed
based on histologic profiles of acute rejection from
human skin-containing VCA.5,9-11 The classification
has been clinically useful in the diagnosis of rejection,
however, the need for characterization of the patho-
logic features and a better understanding of mecha-
nisms remain.12,13 The findings in this study highlight
the potential usefulness of a systematic approach to
evaluation of rejection in allograft biopsies where
pathologic patterns may overlap or not meet qualita-
tive characteristics. The richness of this data allows for
better clinical or research correlation and can give
insights into the varied pathogenesis of rejection in
VCA (e.g., epidermal vs. vascular).
The main features of the global grades of rejection
of the Banff Classification are perivascular inflamma-
tion and epidermal involvement or injury. Similar to
the reports in human VCA, initial biopsies of rejected
porcine skin-containing VCA showed early histologic
lesions which include mild and focal perivascular
inflammation, often by a mononuclear infiltrate,
edema, as well as intraluminal cells in dermal capillar-
ies or venules. In higher grades of rejection, an
increase in perivascular inflammation can be
observed, associated with a lobular expansion of der-
mal vessels and its surrounding stroma. The infiltrate
Figure 6. Endothelialitis (v) and chronic allograft vasculopathy (cav). A) Small artery with endothelialitis (v1) (arrow). B) Artery with
endothelialitis (arrow) and transmural inflammation in an arteriole (arrowheads) (v3). C) Transmural arteritis (v3). Fibrin (arrows) can be
seen in v lesions. D) Early chronic allograft vasculopathy (cav1) in a small artery. E) Severe chronic allograft vasculopathy with luminal
reduction (cav3).
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may also include neutrophils and eosinophils. Epider-
mal involvement typically begins with lymphocytic
infiltration, which may or may not be associated with
spongiosis and basal vacuolation. Hyperkeratosis and
parakeratosis may also be present. The hallmark of
epidermal injury is typically individual cell apoptosis
or dyskeratosis. Frank necrosis and a sloughed epider-
mis are noted in high grade or late stage rejection.
Inflammation of adnexal structures can also be seen
(Fig. 9C & D). These lesions are highlighted and
described in the Banff 2007 Working Classification.
Vascular lesions in VCA, i.e. endarteritis, intraca-
pillary cells, thrombosis and chronic allograft vascul-
opathy, are not part of the Banff current classification.
This scoring system has included vascular lesions
based on observations not only across different grades
of VCA rejection but also because of its prognostic
value in solid organ allografts. In porcine skin-con-
taining VCA, endarteritis can be seen in Grade II to
Grade IV rejection (Fig. 6). Higher c scores are seen in
higher grades of rejection. In the samples analyzed for
predictive value, there was insufficient data to evaluate
v lesions as a predictive factor, however, this parame-
ter has been shown to be predictive of graft outcome
in kidney allografts. In the recent first penile trans-
plantation done in the United States, the second of 2
allograft biopsies showed mild superficial perivascular
inflammation and focal keratinocyte apoptosis, associ-
ated with deep dermal transmural arteriolitis and pan-
niculitis. This was diagnosed as Banff Grade III
Figure 7. Pathologic component scores across accepted and rejected allografts over time (in days). Grafts that rejected and survived for
less than 100 d (black circles) have higher pathologic component scores than grafts that were accepted (white circles).
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rejection and resolved with antithymocyte globulin
and methylprednisolone pulse.14 This further illus-
trates 1) that discordant features may be present, with
relative mild perivascular inflammation in the superfi-
cial dermis but with epidermal apoptosis, and that 2)
endarteritis may suggest a higher grade of rejection
and deep graft inflammation.
In the 2016 International Workshop on VCA His-
topathology, the need for a systematic approach to
pathologic evaluation of VCA in the clinical setting
was raised. Special attention to potential pathologic
features pertaining to antibody-mediated rejection
(AMR) were emphasized. One of the features that has
been clinically reported is capillary thrombosis. Two
clinical cases showed capillary thromboses, one of
which had deep arteriolar thrombosis and relative
sparing of the overlying upper dermis and epider-
mis.15 Capillary thrombosis was seen in early VCA
biopsies and arteries with chronic allograft vaculop-
athy (cav) was observed in later biopsies.15 C4d depo-
sition and (donor-specific antibody) (DSA) were also
present in one case. 15 These reports underline the
need for evaluation for capillary inflammatory lesions
and correlation with C4d and DSA, which offer direc-
tion in understanding antibody-mediated or chronic
rejection pathways in VCA. Moreover, the prognostic
value of these pathologic elements have been
described in solid organ allografts and as such will
likely prove useful in VCA.16 For clinical application,
C4d should be added as a vascular component, but we
did not have a suitable antibody for the pig.
Although there is insufficient data available to
define the specific changes of chronic rejection in
VCA, chronic allograft vasculopathy can be seen in
higher grades of rejection (Fig. 6D, E) and has been
reported in experimental17-19 and human20–21 VCA
Figure 8. A) Animal A3 VCA post-surgical day 13 showing mild edema. B) Animal A3 POD 13 skin biopsy showing minimal perivascular
inflammation (pc1, pa1) and C) no epidermal involvement (ei0, e0). D) Animal B3 POD 14 showing mild edema. E) Animal B3 POD 14
skin punch biopsy showing mild perivascular inflammation (pc1, pa1) but with F) epidermal apoptosis (arrow) and focal necrosis (not
shown) (ei1, e2). G) Animal B1 POD 42 showing erythema. H) Animal B1 POD 42 skin biopsy showing severe perivascular inflammation
(pc3, pa3) and I) lymphocytic infiltration and focal apoptosis (not shown) (ei2, e1).
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studies. The inclusion of cav in the assessment of VCA
will be essential to the understanding of mechanistic
pathways of chronic rejection. Features that have
already been highlighted in the Banff 2007 Working
Classification as indicative of chronic injury include
vascular narrowing, loss of adnexa, skin and muscle
atrophy, fibrosis of deep tissue, myointimal prolifera-
tion and nail changes.5 Experience with long-term or
tolerant VCA22 may be needed to further describe
lesions other than cav that may be of prognostic
significance.
In the design and optimization of this VCA scoring
system and in the test cohort, vascular lesions were
common in high-grade rejection and also show some
evidence of their predictive value. Of note, the depth
of sampling in routine skin biopsies does not always
allow for evaluation of arteries, and early arterial
lesions may be missed. Nonetheless, early recognition
of vascular lesions when vessels are adequate will be
valuable and can expand therapeutic and research
direction.
This paper highlights the value of a pathologic
component scoring system because it subdivides the
pathologic features and identifies other pathologic
components which could elucidate different patterns
and pathways of rejection. Even in this limited cohort,
vascular lesions, for example, are instructive and merit
attention and inclusion in evaluating VCA biopsies.
The findings in this study offer an opportunity to
assess and validate individual pathologic components
for prognostic value. This system is potentially a help-
ful tool for clinical research and should enable the
prospective establishment of clinically important
thresholds of the pathologic components.
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